Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203

Documenti analoghi

• Reproductive adverse events in patients with non‐Hodgkin lymphoma treated with chemotherapeutic regimens including cyclophosphamide, doxorubicin, vincristine, prednisone or CHOP with rituximab: A systematic review and meta‐analysis
  di: Rong Han, et al.
  Pubblicazione: (2024)
• Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment‐naive peripheral T‐cell lymphoma: A multicenter, open‐label, single‐arm, phase 1b trial
  di: Yan Gao, et al.
  Pubblicazione: (2026)
• Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide
  di: Takehiro Miyagi, et al.
  Pubblicazione: (2025)
• Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone ( BV ‐ CHEP ) for the treatment of aggressive adult T‐cell leukaemia/lymphoma
  di: Christopher Dittus, et al.
  Pubblicazione: (2025)
• A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial
  di: Cecilia Carpio, et al.
  Pubblicazione: (2025)